152 related articles for article (PubMed ID: 15901136)
1. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
[TBL] [Abstract][Full Text] [Related]
2. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract][Full Text] [Related]
3. Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report.
Suprasert P; Khunamornpong S
J Med Assoc Thai; 2010 May; 93(5):608-12. PubMed ID: 20524448
[TBL] [Abstract][Full Text] [Related]
4. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
5. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
6. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
Stark A; Lu M; Mackowiak P; Linden M
Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
8. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
9. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer in the 21st century: neu opportunities and neu challenges.
Schnitt SJ
Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
[TBL] [Abstract][Full Text] [Related]
12. cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.
Semiz HS; Pala EE; Can B; Atag E; Gungor H; Sanci M
Turk Patoloji Derg; 2023; 39(1):55-63. PubMed ID: 36178283
[TBL] [Abstract][Full Text] [Related]
13. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
14. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature.
Fotiou S; Hatjieleftheriou G; Kyrousis G; Kokka F; Apostolikas N
Anticancer Res; 2000; 20(3B):2015-20. PubMed ID: 10928144
[TBL] [Abstract][Full Text] [Related]
15. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
16. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
17. [Uterine carcinosarcomas associated with tamoxifen therapy. Report of two cases and review of the literature].
Leung F; Terzibachian JJ; Govyadovskiy A; Bourtembourg A; Aouar Z; Fat BC; Maillet R; Riethmuller D
J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):173-8. PubMed ID: 19135318
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
Tergas AI; Buell-Gutbrod R; Gwin K; Kocherginsky M; Temkin SM; Fefferman A; Lengyel E; Yamada SD
Gynecol Oncol; 2012 Nov; 127(2):316-20. PubMed ID: 22835717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
